Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

November 30, 2001

Primary Completion Date

February 28, 2006

Study Completion Date

May 31, 2013

Conditions
Esophageal Carcinoma
Interventions
DRUG

Tetrathiomolybdate (TM)

Tetrathiomolybdate: 20mg p.o. per day with largest meal. This will be started 4-6 weeks post-op, and continued x 2 years or until progression of disease is documented.

PROCEDURE

Radiation

Radiation treatments will be administered twice per day with each dose separated by more than 6 hours, on Days 1-5, 8-12 and 15-19.

PROCEDURE

Surgery

The persons's esophagus will be surgically removed (esophagectomy) on approximately Day #50.

Trial Locations (1)

48109

University of Michigan Cancer Center, Ann Arbor

All Listed Sponsors
lead

University of Michigan Rogel Cancer Center

OTHER

NCT00176800 - Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma | Biotech Hunter | Biotech Hunter